zopapogene imadenovec
Generic: zopapogene imadenovec·Brand: Papzimeos
zopapogene imadenovec: developed by 1 company · 1 clinical trial tracked.
zopapogene imadenovec evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect zopapogene imadenovec to PGEN; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could zopapogene imadenovec → PGEN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| PRECIGEN, INC. (PGEN) | Phase 2 |
Clinical Trials (1)
Open-Label Study of Zopapogene Imadenovec Retreatment and Vector Shedding Evaluation in Adult Patients With Recurrent Respiratory Papillomatosis
Primary endpoint: Cohort 1 Vector shedding
Interventionalopen30 targetStarted 2024-07Completion 2028-123 sites · United StatesPrecigen, Inc
Frequently asked questions
Who is developing zopapogene imadenovec?
zopapogene imadenovec is being developed by PRECIGEN, INC..
How many clinical trials involve zopapogene imadenovec?
BioSniper tracks 1 clinical trial involving zopapogene imadenovec.